Stockreport

Zenas Bio: Recent IPO With Late-Stage Candidate [Seeking Alpha]

Zenas BioPharma, Inc.  (ZBIO) 
PDF Follow Summary Zenas BioPharma, Inc.'s obexelimab targets CD19 and Fc?RIIb to modulate B-cells, aiming to treat multiple autoimmune diseases with fewer side effects [Read more]